Plate Nº 33 · recorded September 29, 2026
Health & Medicine ResearchReported finding
Gene Editing Converts High-Risk Alzheimer's Gene into Safer Form
Bristol scientists edited the high-risk APOE4 gene into the lower-risk APOE3 form in human immune cells, opening a possible new path to Alzheimer's therapy.
By Elena Vasquez3 min read633 words
In brief
- Researchers converted the high-risk Alzheimer's gene APOE4 into the lower-risk APOE3 using gene editing.
- APOE4 is carried by roughly 1 in 4 people and is one of the strongest genetic risk factors for Alzheimer's.
- The therapy would enter through the bloodstream, bypassing the blood-brain barrier that blocks some existing treatments.
Researchers at the University of Bristol have used gene editing to convert APOE4, the gene that carries the highest inherited risk for Alzheimer's disease, into APOE3, a lower-risk version of the same gene. Dr. Kevin Kemp and his team believe the approach could eventually prevent or slow the disease in people who carry APOE4 — roughly one in four individuals.
The findings, while early-stage, point toward a potential therapy that would work quite differently from existing Alzheimer's drugs. Instead of targeting the downstream hallmarks of the disease, such as amyloid plaques, it would address a genetic risk factor present from birth.
How the study worked
The team worked with human immune blood cells taken from people living with Alzheimer's who also carried APOE4. This choice matters. Human cells let the researchers observe responses as close as possible to what would happen in a real patient's body, rather than in an animal model or a generic cell line.
Using gene editing tools, the researchers rewrote the APOE4 gene into the APOE3 form. Crucially, the editing showed little impact on the rest of the cells' DNA. That off-target precision is a key safety question for any gene-editing therapy, because unwanted cuts elsewhere in the genome could cause harmful mutations. The minimal collateral damage observed here suggests the therapy could be safe, with few unintended effects — though this remains to be confirmed in further work.
Why delivery could be a game-changer
The experimental therapy would be delivered through the bloodstream, which would allow it to bypass the blood-brain barrier and reach the whole brain. The barrier, a tightly packed wall of cells that protects the brain from circulating pathogens and toxins, has partially or completely blocked some Alzheimer's treatments from reaching all brain regions, reducing their effectiveness. A therapy that slips past it could act across the entire organ.
The results so far suggest the experimental gene therapy could be suitable for clinical use. That is an encouraging signal, but the research has so far taken place only in cells in the laboratory. No human trials have been reported, and questions about how the therapy behaves in a living brain — including long-term effects — remain unanswered.
Kemp, an associate professor in the School of Psychology and Neuroscience at the University of Bristol, struck a measured tone: "Our research is still at an early stage, but we're really excited by the results we've seen so far. By targeting the high-risk APOE4 gene, we hope to tackle one of the key risk factors for Alzheimer's and ultimately develop a new treatment for the disease."
A major unmet need
APOE4 is one of the strongest known genetic risk factors for Alzheimer's. Carrying it does not guarantee a person will develop the disease, but it substantially raises the odds. Despite that, no approved therapy currently reduces or prevents APOE4's contribution to Alzheimer's onset.
Liberty Harrison, CEO of BRACE Dementia Research, the charity supporting the work, underlined the gap: "We welcome this exciting development from Kemp. Therapies that can reduce or prevent APOE4 from contributing to the onset of Alzheimer's represent a major unmet clinical need and are urgently required. BRACE is a small charity, and we are proud of the impact we have had on this crucial area of research."
What comes next
For now, the Bristol results amount to a proof of concept in human cells. The path from laboratory gene editing to an approved clinical therapy is long, typically requiring years of animal testing and staged human trials. Still, the study offers a new route: rather than clearing the damage Alzheimer's leaves behind, doctors might one day defuse one of its principal genetic triggers before the disease takes hold.
via Medical Xpress (Source)
More from Elena Vasquez
Nearby plates
- Anti-Aging Drug Boosts Brain Blood Flow in People at Higher Alzheimer's Risk
- New Immune Cell Atlas Links Genetic Variants to Disease Mechanisms
- Alzheimer's Drug Developers Accuse Trial Sites of Faking Data
- Brain Structure Changes May Signal Alzheimer's Years Before Plaques
- Early Statin Use After Diabetes Diagnosis Linked to Lower Dementia Risk